<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419364</url>
  </required_header>
  <id_info>
    <org_study_id>17-0693</org_study_id>
    <secondary_id>1R03HD092370-01</secondary_id>
    <nct_id>NCT03419364</nct_id>
  </id_info>
  <brief_title>Study of Nicotinamide in Early Onset Preeclampsia</brief_title>
  <official_title>Phase II Study of Nicotinamide in Early Onset Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect
      on maternal blood pressure in women with early onset preeclampsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary above
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will receive study agent. 2.5 gm nicotinamide given orally in 3 divided doses (1000 in morning, 500 in afternoon, 1000 at bedtime).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Arterial blood Pressure (MAP)</measure>
    <time_frame>Baseline, 48 hours</time_frame>
    <description>Blood pressure (mmHg) will be used to observe the effect of nicotinamide. The highest MAP (defined as the highest MAP within the 24 hour period prior to the administration of study agent) and the highest MAP at 48 hours after study drug administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with alanine aminotransferase (ALT) =/&gt; 3x Upper Limit of Normal (ULN)</measure>
    <time_frame>Within 24 hours of any dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with aspartate aminotransferase (AST) =/&gt; 3x Upper Limit of Normal (ULN)</measure>
    <time_frame>Within 24 hours of any dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Maternal side effects</measure>
    <time_frame>From initial administration of study agent until 24 hours post last dose</time_frame>
    <description>Maternal side effects are defined as: facial erythema, hives, sore mouth, dry hair, fatigue, flushing, headache, nausea, and heart burn.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Arterial blood Pressure (MAP)</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Blood pressure (mmHg) will be used to observe the effect of nicotinamide. The highest MAP (defined as the highest MAP within the 24 hour period prior to the administration of study agent) and the highest MAP at 7 days after study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women maternal abdominal tenderness</measure>
    <time_frame>From initial administration of study agent until 24 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women with headache unrelieved by oral analgesics</measure>
    <time_frame>From initial administration of study agent until 24 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women with hematocrit decrease of more than 3%</measure>
    <time_frame>From initial administration of study agent until 24 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women with less than 500 cc urine output in 24 hours</measure>
    <time_frame>From initial administration of study agent until 24 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of fetuses with Category III non stress test results</measure>
    <time_frame>From initial administration of study agent until 24 hours post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of fetuses with biophysical profile &lt; 6</measure>
    <time_frame>From initial administration of study agent until 24 hours post last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Nicotinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive study agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotinamide</intervention_name>
    <description>2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday</description>
    <arm_group_label>Nicotinamide</arm_group_label>
    <other_name>niacinamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Diagnosis and Inclusion Criteria

          -  Maternal age 18-55 years

          -  Singleton pregnancy with no known fetal anomalies

          -  Early-onset preeclampsia defined as:

               -  Early-onset: between 24 weeks 0 days and -33 weeks 3 days, based on menstrual
                  dating confirmed by first or second trimester ultrasound OR second trimester
                  ultrasound if menstrual dating unavailable;

               -  Preeclampsia:

          -  New onset hypertension and proteinuria, with systolic BP &gt; 140 mm Hg and/or diastolic
             BP &gt; 90 mm Hg on two occasions 6 hours apart and &gt; 300 mg proteinuria on 24 hour urine
             collection OR urine P/C ratio &gt;0.3;

          -  New onset hypertension and NO proteinuria, with systolic BP &gt; 140 mm Hg and/or
             diastolic BP &gt; 90 mm Hg on two occasions 6 hours apart and one or more of the
             following: serum creatinine &gt;1.1 mg/dL or doubling from baseline ,or central nervous
             system symptoms or visual changes

          -  Severe preeclampsia defined as new onset systolic BP &gt; 160 mm Hg and/or diastolic BP &gt;
             105 with proteinuria as above or or without proteinuria and one or more of the
             following criteria listed above

               -  Candidate for expectant management for at least 48 hours

               -  Deemed clinically stable by primary clinician and candidate for expectant
                  management (delayed delivery) for at least 48 hours;

          -  Maternal liver function tests &lt; 2x ULN

          -  Maternal platelet count &gt; 100,000 mm³

          -  Planned expectant management

          -  Pre-existing medical diseases such as hypertension, diabetes, endocrine disorders,
             gastrointestinal diseases, are well controlled

          -  Fetal well-being established by estimated fetal weight &gt; 5th %tile; normal amniotic
             fluid volume (MVP &gt; 2 cm); normal Umbilical Artery (UA) Dopplers; or reactive Non
             Stress Test (NST) or Biophysical Profile (BPP) &gt; 6

          -  Delivery not anticipated within 48 hours of enrollment

        Exclusion Criteria

          -  Pre-existing renal disease (creatinine &gt; 1.5 mg/dL)

          -  Any pre-existing medical condition that would increase risk for liver toxicity (e.g.
             hepatitis B or C; HIV; Isoniazid (INH) use)

          -  Eclampsia; cerebral edema on CT/MRI; headache unrelieved by analgesics

          -  Evidence of liver dysfunction (LFTs &gt; 2x ULN)

          -  Thrombocytopenia (platelets &lt; 100,000 mm³)

          -  Pulmonary edema

          -  HELLP syndrome

          -  Evidence of fetal compromise: Estimated Fetal Weight (EFW) &lt; 5th percentile; or BPP &lt;
             6; or absent or reverse diastolic UA blood flow; or oligohydramnios (MVP &lt; 2 cm)

          -  Placental abruption defined as unexplained vaginal bleeding

          -  Preterm labor defined as regular contractions and cervical change

          -  Any condition deemed by the investigator to be a risk to mother or fetus in completion
             of the study

          -  Any condition deemed by the investigator to require delivery within 48 hours
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Study of pregnant women only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Boggess, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC_Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Dorman, RN</last_name>
    <phone>984-974-9012</phone>
    <email>kdorman@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UNC at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Dorman, RN</last_name>
      <phone>984-974-9012</phone>
      <email>kdorman@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Kim Boggess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

